|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 硫糖铝联合兰索拉唑及莫沙必利治疗胃食管反流性疾病临床实验研究显示文摘目的:探讨硫糖铝、兰索拉唑、莫沙必利联合治疗胃食管反流病的临床疗效。方法:根据大样本随机、对照、双盲试验原则,我们从样本库中随机抽取了50例患者数据且随机分为两组,观察组和对照组,各25例。两组患者在年龄、性别、疾病史等方面均无显著性差异。观察组治疗方法为:硫糖铝1.0 g,3次/d,饭前1 h嚼服;兰索拉唑30 mg,1次/d,饭前30 min服用;莫沙必利5 mg,3次/d,饭前30 min服用。对照组为:奥美拉唑20 mg,2次/d,饭前30 min服用;多潘立酮10 mg,3次/d,饭前30 min服用。两组均以6 w为1个疗程,疗程结束后我们综合对比了两组的临床疗效(烧心、反酸、胸骨后痛、吞咽不适等)及不良反应,并复查胃镜。结果:观察组的临床有效率为96%,明显高于对照组的临床有效率74%,该结果具有统计学意义,但两组差异无统计学意义(P>0.05)。胃镜下食管炎愈合及炎症改善情况:治疗组86%,对照组70%,两者比较差异有显著性(P<0.05),但两组差异无统计学意义(P>0.05)。结论:硫糖铝、兰索拉唑、莫沙必利联合治疗反流性食管炎的临床疗效明显优于非联合用药的疗效,值得进一步在临床上推广和应用。 | 李大英 | 2016 | 大家健康(学术版)2016，，1： | 2 |
| 2 | 中药与免疫调节剂辅助治疗复治肺结核的临床分析显示文摘目的:对应用中药结核丸与免疫调节剂联合对患有肺结核疾病患者在接受复治期间实施辅助性治疗的临床效果进行研究。方法:选择在我中心收治的患有肺结核疾病患者48例,随机分为对照组、研究1组、研究2组,平均每组16例。采用常规抗结核治疗方案对对照组研究对象实施肺结核疾病复治;在常规抗结核治疗方案基础上,加用母牛分枝杆菌菌苗对研究1组研究对象实施肺结核疾病复治;在研究1组治疗方案基础上,加用中药结核丸对研究2组研究对象实施肺结核疾病复治。对比三组研究对象的肺结核疾病复治的治疗效果、痰菌检测结果转阴时间、检查显示病灶明显吸收时间、肺结核疾病复治计划实施总时间、在抗结核疾病治疗期间出现的药物相关不良反应人数。结果:研究2组研究对象肺结核疾病复治的治疗效果明显优于研究1组和对照组,组间差异显著(P<0.05);研究1组研究对象肺结核疾病复治的治疗效果明显优于对照组,组间差异显著(P<0.05)。研究2组研究对象的痰菌检测结果转阴时间、检查显示病灶明显吸收时间、肺结核疾病复治计划实施总时间明显短于研究1组和对照组,组间差异显著(P<0.05);研究1组研究对象的痰菌检测结果转阴时间、检查显示病灶明显吸收时间、肺结核疾病复治计划实施总时间明显短于对照组,组间差异显著(P<0.05)。研究2组研究对象在抗结核疾病治疗期间出现的药物相关不良反应人数明显少于研究1组和对照组,组间差异显著(P<0.05);研究1组研究对象在抗结核疾病治疗期间出现的药物相关不良反应人数明显少于对照组,组间差异显著(P<0.05)。研究2组外周血T细胞亚群水平在用药前后的变化情况明显好于研究1组和对照组,组间差异显著(P<0.05)。结论:应用中药结核丸与免疫调节剂联合对患有肺结核疾病患者在接受复治期间实施辅助性治疗的临床效果非常明显。 | 陆志江 | 2016 | 大家健康(学术版)2016，，2： | 2 |
| 3 | Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton-pump inhibitors显示文摘AIM:To identify objective and subjective predictors for the reliable diagnosis of gastroesophageal reflux disease(GERD)and the response to proton pump inhibitor(PPI)therapy.METHODS:Retrospectively,683 consecutive patients suspected for GERD who underwent pH-metry/impedance measurement(pH/MII)were analyzed.All patients had previously undergone standard PPI treatment(e.g.,pantoprazole 40 mg/d or comparable).Four hundred sixty patients were at least 10 d off PPIs(group A),whereas 223 patients were analyzed during their ongoing PPI therapy(group B).In addition,all patients completed a standardized symptom-and lifestyle-based questionnaire,including the therapeutic response to previous PPI trials on a 10-point scale.Uniand multivariance analyses were performed to identify criteria associated with positive therapeutic response to PPIs.RESULTS:In group A,positive predictors(PPs)for response in empirical PPI trials were typical GERD symptoms(heartburn and regurgitation),a positive symptom index(SI)and pathological results in pH/MII,along with atypical symptoms,including hoarseness and fullness.In group B,regular alcohol consumption was associated with the therapeutic response.The PPs for pathological results in pH/MII in group A included positive SI,male gender,obesity,heartburn and regurgitation.In group B,the PPs were positive SI and vomiting.Analyzing for positive SI,the PPs were pathological pH and/or MII,heartburn regurgitation,fullness,nausea and vomiting in group A and pathological pH and/or MII in group B.CONCLUSION:Anamnestic parameters(gender,obesity,alcohol)can predict PPI responses.In non-obese,female patients with non-typical reflux symptoms,pH/MII should be considered instead of empirical PPIs. | Valentin Becker Stefan Grotz Christoph Schlag Simon Nennstiel Analena Beitz Bernhard Haller Roland M Schmid Alexander Meining Monther Bajbouj | 2014 | World Journal of Gastroenterology2014，20，14： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员